IDH2 and neoplasm: Univariate analysis showed a significant better survival in patients with a younger age (p = 0.000), higher EOR (p = 0.000), methylated MGMT promoter (p = 0.000), mutation of IDH1/IDH2 genes (p = 0.033), presence of lower residual tumor (p = 0.000) and lower preoperative ΔT1/T2 MRI Index (p = 0.000) (Figure 2).